Special Issue

Discovery and Development of Novel Antibacterial Agents— 2nd Edition

Message from the Guest Editor

The first volume of the Special Issue "Discovery and Development of Novel Antibacterial Agents" was published in September 2022. It was a success, encouraging us to open a second volume on the same topic. As a continuation of the first Special Issue, this second volume will also focus on the following topics: (1) The discovery of novel antibacterial natural products derived from microbial organisms, plants, etc.; (2) The identification and conformation of potential

- (2) The identification and conformation of potential antibacterial targets, particularly in Gram-negative bacteria;
- (3) A deep mechanistic understanding of the diverse ways to revitalize existing antibiotics, to shed light on developing rational medication;
- (4) The interaction between pathogenic bacteria and hosts (including either host cells or symbionts) in modulating infection dynamics and colonization resistance.

Guest Editor

Prof. Dr. Kui Zhu

College of Veterinary Medicine, China Agricultural University, Beijing, China

Deadline for manuscript submissions

30 June 2026



an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



mdpi.com/si/214718

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/ antibiotics





an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery. use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. Antibiotics is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

